Business Context and Reporting Period
This Form 6-K filing covers the month of September 2009 for Sanofi-Aventis, a foreign private issuer headquartered in Paris, France. The report serves to incorporate by reference two press releases issued during the period regarding legal proceedings and research initiatives.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing referencing external press releases rather than a financial statement.
Material Changes and Corporate Events
- Legal Resolution: On September 28, 2009, the company announced the dismissal of a U.S. securities law suit concerning its drug Zimulti (rimonabant).
- Research Initiative: On September 29, 2009, Sanofi-Aventis launched a major insulin research program in partnership with the international scientific community.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or a discussion of general risks. The primary risk-related update is the resolution of the specific litigation regarding Zimulti, which was dismissed.
Investor Verification Checklist
- Verify the details of the dismissed U.S. securities lawsuit regarding Zimulti (rimonabant) in the attached press release (Exhibit 99.1).
- Review the scope and partnership details of the new insulin research program announced on September 29, 2009 (Exhibit 99.2).
- Consult the company's most recent Form 20-F or quarterly financial reports for actual financial metrics, as this Form 6-K does not contain them.